Fulgent Genetics Analyst Ratings
Fulgent Genetics Analyst Ratings
Date | Upside/Downside | Analyst Firm | Price Target Change | Rating Change | Previous / Current Rating |
---|---|---|---|---|---|
11/14/2022 | 65.65% | Piper Sandler | $70 → $65 | Maintains | Overweight |
08/25/2022 | 65.65% | Credit Suisse | → $65 | Initiates Coverage On | → Outperform |
05/16/2022 | 78.39% | Piper Sandler | $85 → $70 | Maintains | Overweight |
01/25/2022 | 218.55% | Oppenheimer | $141 → $125 | Maintains | Outperform |
08/10/2021 | 65.65% | Credit Suisse | $55 → $65 | Maintains | Underperform |
03/05/2021 | 256.78% | Piper Sandler | $135 → $140 | Maintains | Overweight |
02/01/2021 | 231.29% | Oppenheimer | $75 → $130 | Maintains | Outperform |
01/08/2021 | — | Credit Suisse | Downgrades | Neutral → Underperform | |
11/24/2020 | — | BTIG | Downgrades | Buy → Neutral | |
09/25/2020 | 7.03% | Credit Suisse | $13 → $42 | Maintains | Neutral |
08/20/2020 | 91.13% | Oppenheimer | → $75 | Initiates Coverage On | → Outperform |
07/27/2020 | -21% | Piper Sandler | $21 → $31 | Maintains | Overweight |
06/17/2020 | -46.48% | Piper Sandler | $18 → $21 | Maintains | Overweight |
05/29/2020 | -49.03% | BTIG | → $20 | Initiates Coverage On | → Buy |
05/05/2020 | -71.97% | Credit Suisse | $12 → $11 | Maintains | Neutral |
11/05/2019 | -68.65% | Piper Sandler | $9.5 → $12.3 | Upgrades | Neutral → Overweight |
04/26/2019 | — | Credit Suisse | Downgrades | Outperform → Neutral | |
05/09/2018 | -87.26% | Credit Suisse | $6 → $5 | Maintains | Outperform |
03/01/2018 | — | Piper Sandler | Downgrades | Overweight → Neutral | |
03/01/2018 | -84.71% | Credit Suisse | $6.5 → $6 | Maintains | Outperform |
日期 | 上行/下行 | 分析公司 | 目標價格變動 | 評級變動 | 之前/當前的評級 |
---|---|---|---|---|---|
11/14/2022 | 65.65% | 派珀·桑德勒 | 70 美元 → 65 美元 | 維護 | 超重 |
08/25/2022 | 65.65% | 瑞士信貸 | → 65 美元 | 啓動覆蓋範圍開啓 | → 跑贏大盤 |
05/16/2022 | 78.39% | 派珀·桑德勒 | 85 美元 → 70 美元 | 維護 | 超重 |
01/25/2022 | 218.55% | 奧本海默 | 141 美元 → 125 美元 | 維護 | 跑贏大盤 |
08/10/2021 | 65.65% | 瑞士信貸 | 55 美元 → 65 美元 | 維護 | 表現不佳 |
03/05/2021 | 256.78% | 派珀·桑德勒 | 135 美元 → 140 美元 | 維護 | 超重 |
2021 年 1 月 2 日 | 231.29% | 奧本海默 | 75 美元 → 130 美元 | 維護 | 跑贏大盤 |
01/08/2021 | — | 瑞士信貸 | 降級 | 中性 → 跑贏大盤 | |
11/24/2020 | — | BTIG | 降級 | 買入 → 中性 | |
2020 年 9 月 25 日 | 7.03% | 瑞士信貸 | 13 美元 → 42 美元 | 維護 | 中立 |
2020 年 8 月 20 日 | 91.13% | 奧本海默 | → 75 美元 | 啓動覆蓋範圍開啓 | → 跑贏大盤 |
07/27/2020 | -21% | 派珀·桑德勒 | 21 美元 → 31 美元 | 維護 | 超重 |
2020 年 6 月 17 日 | -46.48% | 派珀·桑德勒 | 18 美元 → 21 美元 | 維護 | 超重 |
2020 年 5 月 29 日 | -49.03% | BTIG | → 20 美元 | 啓動覆蓋範圍開啓 | → 購買 |
05/05/2020 | -71.97% | 瑞士信貸 | 12 美元 → 11 美元 | 維護 | 中立 |
11/05/2019 | -68.65% | 派珀·桑德勒 | 9.5 美元 → 12.3 美元 | 升級 | 中性 → 超重 |
04/26/2019 | — | 瑞士信貸 | 降級 | 跑贏大盤 → 中性 | |
2018 年 9 月 5 日 | -87.26% | 瑞士信貸 | 6 美元 → 5 美元 | 維護 | 跑贏大盤 |
03/01/2018 | — | 派珀·桑德勒 | 降級 | 超重 → 中性 | |
03/01/2018 | -84.71% | 瑞士信貸 | 6.5 美元 → 6 美元 | 維護 | 跑贏大盤 |
What is the target price for Fulgent Genetics (FLGT)?
富爾金特遺傳學(FLGT)的目標價格是多少?
The latest price target for Fulgent Genetics (NASDAQ: FLGT) was reported by Piper Sandler on November 14, 2022. The analyst firm set a price target for $65.00 expecting FLGT to rise to within 12 months (a possible 65.65% upside). 4 analyst firms have reported ratings in the last year.
派珀·桑德勒於2022年11月14日公佈了富爾金特遺傳學(納斯達克股票代碼:FLGT)的最新目標股價。該分析公司將目標股價定爲65.00美元,預計FLGT將在12個月內升至12個月內(可能上漲65.65%)。去年有4家分析公司公佈了評級。
What is the most recent analyst rating for Fulgent Genetics (FLGT)?
Fulgent Genetics(FLGT)的最新分析師評級是多少?
The latest analyst rating for Fulgent Genetics (NASDAQ: FLGT) was provided by Piper Sandler, and Fulgent Genetics maintained their overweight rating.
派珀·桑德勒對富爾金特遺傳學(納斯達克股票代碼:FLGT)的最新分析師評級由派珀·桑德勒提供,富爾金特遺傳學維持增持評級。
When is the next analyst rating going to be posted or updated for Fulgent Genetics (FLGT)?
Fulgent Genetics(FLGT)的下一次分析師評級何時發佈或更新?
Analysts arrive at stock ratings after doing extensive research, which includes going through public financial statements, talking to executives and customers of Fulgent Genetics, and listening in to earnings conference calls. Most analysts do this every three months, so you should get 4 ratings per company per firm each year. The last rating for Fulgent Genetics was filed on November 14, 2022 so you should expect the next rating to be made available sometime around November 14, 2023.
分析師在進行了廣泛的研究後得出了股票評級,其中包括瀏覽公開財務報表,與Fulgent Genetics的高管和客戶交談,以及聽取業績電話會議。大多數分析師每三個月做一次這樣的評級,因此每家公司每年應該獲得4次評級。富爾金特遺傳學的最新評級是在2022年11月14日發佈的,因此您應該預計下一個評級將在2023年11月14日左右公佈。
Is the Analyst Rating Fulgent Genetics (FLGT) correct?
分析師對富爾金特遺傳學(FLGT)的評級是否正確?
While ratings are subjective and will change, the latest Fulgent Genetics (FLGT) rating was a maintained with a price target of $70.00 to $65.00. The current price Fulgent Genetics (FLGT) is trading at is $39.24, which is out of the analyst's predicted range.
儘管評級是主觀的,並且會發生變化,但最新的富爾金特遺傳學(FLGT)評級維持不變,目標股價爲70.00美元至65.00美元。富爾金特遺傳學(FLGT)目前的交易價格爲39.24美元,超出了分析師的預期區間。